• NCI CTCAE Version 3.0 (v3.0) Grade 2 hand-foot skin reaction (HFSR) [palmar-plantar
erythrodysesthesia (PPE)] that is recurrent or does not improve within 7 days despite dose
reduction; interrupt therapy for a minimum of 7 days for Grade 3 HFSR
• Symptomatic Grade 2 hypertension
• Any NCI CTCAE v3.0 Grade 3 or 4 adverse reaction